Aurobindo Pharma’s wholly owned subsidiary - Aurobindo Pharma Australia Pty - has received approvals from Therapeutic Goods Administration (TGA), Government of Australia for registration of Risperidone Tablets 0.5mg, 1mg,2mg, 3mg, 4mg and Oral Solution 1mg/1ml and Alendronate Tablets 70mg.
Risperidone Tablets and Oral Solution are indicated in the treatment schizophrenia and falls under the neurological (CNS) segment. Alendronate Tablets 70mg are indicated for the treatment and prevention of osteoporosis.
Risperdione products have market size of approximately $27.5 million and Alendronate has $14million for twelve months ending September 2010 according to IMS. The company now has 8 approvals from TGA, Australia.
The company has registered growth of 12.51% in its net profit for the current year, 2011 at Rs 593.80 crore as compared to Rs 527.76 crore for the previous year. Its total income has increased by 26.44% at Rs 4141.11 crore for the year under review from Rs 3275.08 crore in previous year.
On consolidated basis, the group’s net profit for the year has increased marginally by 0.01% at Rs 563.45 crore as compared to Rs 563.40 crore for the previous year. Total income for the year has increased by 21.92% at 4406.67 crore as compared to Rs 3614.37 crore for the previous year
Aurobindo Pharma is the market leader in semi-synthetic penicillin drugs. It has presence in key therapeutic segments like SSPs, cephalosporins, anti-retrovirals, CNS, cardio-vascular, gastroenterology, etc
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |